A B S T R A C T The immunoreactive parathyroid hormone (iPTH) To reexamine this question, we fractionated peripheral and thyroid or parathyroid venous effluent sera from four patients with primary hyperparathyroidism using a high-resolution gel filtration system (Bio-Gel P-150 columns run by reverse flow). The column effluents were analyzed using two PTH radioimmunoassays, one directed toward the amino(NH2)-terminal region of the molecule, the other toward the COOHterminal region.
A B S T R A C T The immunoreactive parathyroid hormone (iPTH) in the plasma of hyperparathyroid man consists largely of carboxyl (COOH)-terminal fragments of the hormone. Although these fragments have been thought to arise principally or solely from peripheral metabolism of intact human PTH {hPTH(l-84)} secreted from the parathyroid gland, there is disagreement about the source of iPTH fragments in vivo.
To reexamine this question, we fractionated peripheral and thyroid or parathyroid venous effluent sera from four patients with primary hyperparathyroidism using a high-resolution gel filtration system (Bio-Gel P-150 columns run by reverse flow). The column effluents were analyzed using two PTH radioimmunoassays, one directed toward the amino(NH2)-terminal region of the molecule, the other toward the COOHterminal region.
In all four thyroid or parathyroid venous effluent sera studied, iPTH was 9-180 times higher than in peripheral serum from the same patient; after fractionation, hPTH(1-84) accounted for only a portion of the total iPTH (35-55% with the assay directed toward the COOH-terminal region of hPTH, >90% with the NH2-terminal directed assay.) The remaining iPTH eluted from Bio-Gel P-150 after hPTH(1-84) as NH2-or COOH-terminal hPTH fragments. These results suggest that parathyroid tumors secrete large quantities of hPTH fragments. Based on estimates of their molar concentrations in serum, tumor-secreted COOHterminal hPTH fragments could account for most of these peptides in peripheral serum if their survival times were, as estimated by several other workers, [5] [6] [7] [8] [9] [10] times that of hPTH .
We conclude that, in contrast to published information, secretory products of hyperfunctioning parathyroid tissue are probably a major source of serum PTH immunoheterogeneity.
INTRODUCTION
As is the case for several other peptide hormones (1) , there has been keen interest in the molecular forms of parathyroid hormone (PTH)1 and its fragments that circulate in human blood. In 1968, Berson and Yalow made the novel observation that PTH in the plasma of patients with hyperparathyroidism is immunoheterogeneous (2) , and several laboratories have subsequently confirmed and expanded on their findings (3) (4) (5) (6) . Recently, it has been shown that the immunoreactive PTH (iPTH) in hyperparathyroid plasma consists principally of at least two hormonal forms: intact PTH {PTH(1-84)} and carboxyl (COOH)-terminal fragments of PTH(1-84) (7) (8) (9) (10) (11) (12) (13) . There is also general agreement that the concentration of COOH- terminal PTH fragments in such plasma is 5-10 times higher than that of PTH ; this concentration difference is thought to be due to the longer survival time of these COOH-terminal fragments in plasma (5, 8, 14) .
The important question of where these PTH fragments originate is unsettled. Two alternatives have been proposed. The first is that PTH fragments are derived almost exclusively from peripheral metabolism of secreted hPTH(1-84) (15) . Potts et al. (6, 9, (15) (16) (17) (18) (19) have reported that virtually all of the IPTH in venous effluent blood from parathyroid adenomas coeluted with "3'I-bovine PTH [bPTH(1-84)] after gel filtration on columns of Bio-Gel P-10 (Bio-Rad Laboratories, Richmond, Calif.). These researchers have also demonstrated specific and sensitive cleavage of exogenously administered PTH(1-84) and labeled PTH(1-84) in several animal species (9, 20, 21) . The second alternative is that PTH fragments are directly secreted from parathyroid tissue; before information was available concerning the molecular forms of iPTH in plasma, Arnaud et al. (3, 4) , and Sherwood et al. (22) showed that PTH fragments were released into the medium by parathyroid adenoma explants cultured in vitro.
Recently Radioimmunoassays and specificity of antisera. The methods used have been described in detail (24) and were employed with minor modifications for all radioimmunoassays of PTH done on whole serum and on gel-filtration columneffluent fractions. In brief, our procedures involved the preincubation of antiserum, standard or unknown in 300 ,ul of assay diluent (0.1 M sodium barbital buffer, pH 8.6, containing 10% hypoparathyroid plasma and 500 kallikrein inactivator units Trasylol/ml) for 3 days, shaking at 4°C, followed by 2 more days of incubation with 1311-bPTH(1-84) added in 200 ,ul of assay diluent (total incubation volume, 500 ,ul). Separation ofantibody-bound from "free" (B/F) tracer was carried out with dextran-coated charcoal by a modification (24) of the procedure of Herbert et al. (26) . The quality control measures reported (24) were also used in the present studies. In particular, for a valid iPTH measurement we required that: (a) addition of unknown serum specimens or column fractions produced decreases in the B/F ratio at least 2 SD greater than the mean B/F ratios obtained with the same quantities of hypoparathyroid serum or column buffer processed in the same way as column fractions containing iPTH; and (b) iPTH values obtained from measurements of at least two but usually three or more dilutions of the same unknown serum or column fractions were within ±10% of each other.
bPTH(1-84) isolated by described procedures (27, 28) was labeled with 131I (29) and used as the tracer in all radioimmunoassays. Homogeneous hPTH(1-84) (30) was used as standard. In the radioimmunoassays with antiserum GP1M the standard curve produced by multiple dilutions of hyperparathyroid serum was parallel to the curve produced by hPTH(1-84) over its initial two-thirds, however, the curves diverged at higher concentrations (11) . Only the initial twothirds of the hPTH(1-84) standard curve was therefore used to determine iPTH values with this antiserum. With antiserum CH14M, however, the immunodilution curves of hyperparathyroid serum and hPTH(1-84) were completely parallel (11) .
PTH was measured with two radioimmunoassay systems which have markedly different specificities for regions of the PTH molecule (11) . One, with GP1M antiserum at a final dilution of 1:75,000, is directed primarily toward the COOHterminal region of PTH and is therefore designated "anti-C".
In this system, as little as 10 pg of hPTH(1-84) competitively inhibits the binding of 13'I-bPTH(1-84), but no inhibition of this binding is observed with 10,000-fold (100 ng) greater quantities of either of the synthetic amino(NH2)-terminal peptides bPTH(1-34) (31) or hPTH(1-34).2 The other assay system is primarily directed toward the NH2-terminal region of PTH. It uses CH14M antiserum at a final dilution of 1:2,000 and is designated "anti-N". In contrast to the anti-C system, the anti-N assay has virtually equivalent recognition for hPTH(1-84) and the synthetic NH2-terminal peptides, bPTH , and hPTH(1-34) (11).
It should be stated, however, that definitive characterization of these antisera with respect to their ability or inability to recognize the COOH-terminal region ofhuman PTH depends upon the results of studies with pure COOH-terminal fragments of hPTH. These peptide fragments are currently not available, and to the authors' knowledge, no reported PTH radioimmunoassay system has been characterized in this way. Therefore, we emphasize that our operational assumptions regarding the specificity characteristics of the two assay systems, used in the present studies, are valid only within the limits of the specificity studies we have done with human intact PTH obtained from natural sources and its synthetic amino-terminal fragment, hPTH .
Gelfiltration. The methods used (10) have been modified for these studies. Columns (2.6 x 90 cm, Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N.J.) of Bio-e4-P-150 (100-20 mesh; Bio-Rad Laboratories) were developed by reverse (ascending) flow at 4°C in 0.2 M ammonium-acetate buffer (pH 4.6). A constant flow rate of 6.5 ml/h was maintained using a Polystaltic Pump (Buchler Instruments Div., Searle Analytic Inc., Fort Lee, N. J.) and fractions were collected in 4.5-to 4.9-ml volumes in 25 x 80-mm flint glass vials (Amersham/Searle Corp., Arlington Heights, Ill.).
Serum samples to be gel filtered were thawed after storage for no longer than 6 mo, brought to a temperature of 40C, and centrifuged at 10,000 x g for 15 min at 4°C. Each patient's peripheral, parathyroid or thyroid venous serum samples were applied separately to columns in the same volume (1-2 ml). In a separate experiment designed to determine if blood was capable of degrading PTH, 100 ng of homogeneous hPTH(1-84) was incubated in 5 ml of normal whole blood at 220C for 1 h. The serum was removed after centrifugation, frozen at -200C for 2 wk, and finally thawed, centrifuged, and gel filtered (1 ml) with the same procedures as described for hyperparathyroid sera. Immediately before application to columns, tracer amounts (_20,000 cpm) of 131I-bPTH(1-84), 125I-bPTH(1-34), and '25I were added to each serum sample as column markers. Individual column fractions contained quantities of radioactivity which were well below levels that might have interfered with radioimmunoassays (<100 pg iPTH). The void volume (V0) was indicated by the elution position of the largest serum protein component as determined by optical density determina2The amino acid sequence of the synthetic hPTH(1-34) (32) used in these studies was that reported by Brewer et al. (33, 34) . A somewhat different amino acid sequence of hPTH(1-34) has been independently determined by others (35, 36) .
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tions at 280 nm, and the salt volume (Vu) was determined by the elution position of "-I. Kd of the components in column effluents was calculated by the following formula: Kd = (elution volume of substance -Vo)/(V1 -Vo).
Fig . 1A shows a representative gel-filtration profile using this fractionation system for separation of the calibration mixture of 311-bPTH(1-84), 125I-bPTH(1-34), and 125I which were added to 10 ml of hypoparathyroid plasma before (B) Gel filtration of a 1-ml sample of serum from normal whole blood to which 100 ng homogeneous hPTH (1-84) had been added (details of incubation in Methods); column fractions were analyzed for iPTH after lyophilization (see text for details) using the anti-N assay (CH14 antiserum, 0) and the anti-C assay (GP1M antiserum, 0). Assay standard, homogeneous hPTH (1-84). Recovery of iPTH (both assays) was >75%. Shaded area represents the optical density readings at 280 nm of 1:10 dilutions of the column fractions. (x), iPTH (anti-N and anti-C assays) in lyophilized column fractions after gel filtration of 10 ml serum from a patient with post-surgical hypoparathyroidism. The detection limit for iPTH in all assays was -0O.1 ng eq hPTH(1-84)/fraction. The void volume (V0), the salt volume (Vj), and the elution positions of radioactive internal markers are indicated by the arrows.
chromatography. The resolution of these marker components is excellent: 131I-bPTH(1-84) (Kd = 0.297) is separated by about 50 ml from the elution position of the most retained serum protein component and 1311-bPTH(1-34) (Kd = 0.565) elutes about 180 ml before the salt volume. For nine column runs the mean Kd (±SD) for the 131I-bPTH(1-84) markers was 0.301±0.005 and for the 13'I-bPTH(1-34) marker was 0.556±0.021. Fig. 1B shows that homogeneous hPTH(1-84) preincubated in whole blood as described elutes as a single immunoreactive component from these columns -15 ml before the 13'I-bPTH(1-84) marker; the anti-N and anti-C assays measured hPTH(1-84) identically in effluent fractions processed as described below. These results indicate that detectable quantities of hPTH fragments are not generated from hPTH( 1-84) under the conditions we used for processing blood and serum. No iPTH could be detected in column fractions when 10 ml of serum from a surgically hypoparathyroid patient was gel filtered and lyophilized as described below.
Systematic processing of effluent fractions included: (a) assay of radioactivity by gamma scintillation counting (2-inch well, Auto-Gamma Instrument, Searle Analytic Inc., Des Plaines, Ill.) at 22°C (total counting time 1.5 h); (b) optical density measurements at 280 nm of those column fractions containing serum proteins; (c) individual shell freezing of fractions; (d) lyophilization twice to remove ammonium acetate; (e) storage of the dried fractions at -20°C; (f) solvation with 1 ml of assay diluent (refer to section on radioimmunoassay procedures); and (g) radioimmunoassay. Steps a-f were carried out in the same vials in which column fractions had been collected. Equal volumes of column buffer which had passed through gel-filtration columns before elution of serum proteins were processed in the same way as column fractions containing iPTH; the twice lyophilized residues were analyzed as radioimmunoassay "blanks" or used in control incubations for samples containing iPTH.
RESULTS
Assays of unfractionated hyperparathyroid sera (Table II) . All values for serum iPTH were consistently greater when measured with the anti-C assay (GP1M antiserum) than with the anti-N assay (CH14M antiserum). The difference between iPTH values determined by the two assays was statistically significant (P < 0.014 by rank-sum test [37] ) only in peripheral sera, however. In these sera, iPTH averaged 7.2 ng eq hPTH(1-84)/ml when determined with the anti-C assay and 1.6 ng eq hPTH(1-84)/ml when determined with the anti-N assay.
In thyroid or parathyroid venous effluent sera, we measured consistently greater quantities of iPTH with the anti-C assay (mean, 203 ng eq hPTH(1-84)/mi) than with the anti-N assay (mean, 143 ng eq hPTH(1-84)/ml). However, this difference was not statistically significant, probably because of the marked variation in total serum iPTH values from one patient to another. On the other hand, the ratio of anti-C iPTH to anti-N iPTH in these sera (mean±+-SD, 1.4-+ 0.1 ng hPTH(1-84)/ml) was significantly greater (P < 0.001) than the ratio of 1.0 observed when iPTH was measured in hypoparathyroid serum to which homogeneous 1370 Flueck, Di Bella, Edis, Kehrwald, and Arnaud 5 Significantly greater than the ratio of 1.0 observed when iPTH was measured in hypoparathyroid serum (P < 0.001) (37) to which highly purified hPTH(1-84) had been added. 11 For the difference between the iPTH values determined by anti-N and anti-C assays; the rank-sum test was used for statistical analysis (37) .
hPTH(1-84) had been added. These observations suggested that COOH-terminal fragments of hPTH were present in thyroid or parathyroid venous effluents in addition to intact hormone. A 9.3-fold or greater "step-up" increase was observed in all four thyroid or parathyroid venous effluent sera when compared to their respective peripheral sera (range, 9.3-to 183-fold). These large step-up increases indicate that the iPTH which we measured in thyroid or parathyroid venous effluent was derived largely from parathyroid tissue.
Step-up increases were consistently greater when iPTH was measured with the anti-N assay (range, 38-to 183-fold; mean, 89-fold) than with the anti-C assay (range, 9.3-to 68-fold; mean, 23-fold). However, this difference was not due, as suggested (38) , to relatively greater quantities of iPTH in thyroid or parathyroid venous effluents when measured with the anti-N assay. There was actually less iPTH in these sera. The greater step-up difference observed with the anti-N assay resulted from the much lower quantities of iPTH in peripheral sera measured with this assay than measured with the anti-C assay.
Serum fractionation on Bio-Gel P-150 columns.
Gel-filtration patterns of iPTH (anti-C assay only) in the four thyroid or parathyroid venous effluent sera studies are shown in Fig. 2A-D . The corresponding pattern for iPTH in an equal volume of peripheral serum from each patient, shown for comparison, confirms that iPTH in peripheral serum made only a small contribution (<10% in all cases) to the total iPTH observed in the patient's thyroid or parathyroid venous effluent serum. We consistently observed a large peak of immunoreactivity in all four thyroid or parathyroid venous effluent sera that eluted just before the 1311_ bPTH(1-84) marker. Mean Kd (±SD) for this component in four column runs was 0.271±0.007, and it reacted equally well in both anti-C and anti-N assays (Fig. 3A) . We interpreted these observations to indicate that this peak corresponded to hPTH .
In addition to intact hPTH, however, we consistently observed large quantities of iPTH in all four thyroid or parathyroid venous effluent sera studied that eluted after hPTH(1-84) but well before the salt volume; the Kd for these iPTH components ranged from -0. 35   Human Parathyroid Hormone 32   28   24   20 131 I-PTH I-bPTH -0.35-0.6 gave only a series of iPTH peaks with 1-,4) "0+M' these same Kd values; no immunoreactivity could be detected in the region of the elution pattern corresponding to hPTH(1-84) (data not shown). B-ll Examination (anti-N and anti-C assays) of the iPTH in thyroid venous effluent serum from patient I after gel filtration (Fig. 3A) showed that -90% of the iPTH detected in the anti-N assay (determined by integration) consisted of hPTH (1-84) . The remainder consisted of an iPTH component with Kd of 0.4-0.5 which reacted predominantly in the anti-N assay. We interpreted these observations to indicate the presence of an NH2-terminal PTH fragment. Three of the four thyroid or parathyroid venous effluent sera (I, II, and IV) contained this iPTH fragment (data not shown), and it comprised 5-10% of the total iPTH measured with the D-1 anti-N assay in these three sera. (Tables I and II) . For simplicity, the regions of the elution profiles representing the optical densities (at 280 nm) of the serum proteins are not shown. Details of the gel filtration and processing of the fractions are in the text. Column fractions (after lyophilization) were analyzed for iPTH with the anti-C assay (GP1M antiserum). (0), sera obtained from thyroid (A and B) or parathyroid (C and D) veins; (0), peripheral serum. The volumes of thyroid or parathyroid and peripheral serum gel filtered for each individual patient were the same: A, 1.8 ml; B, 1.0 ml; C, 2.0 ml; D, 1.0 ml. The arrows show the elution positions ofradioactive internal markers. The detection limit for iPTH in all assays was -0.1 ng eq hPTH (1-84)/fraction. Recoveries of iPTH ranged from -S50 to 70% and were not significantly different between thyroid or parathyroid and peripheral sera.
to 0.6. Integration of these four gel-filtration profiles showed that -30-50% of the total iPTH in thyroid or parathyroid venous effluent sera consists of these immunoreactive PTH fragments. Rechromatography of the iPTH component in parathyroid venous effluent serum witi a Kd of 0.27 using the same column system again showed a single symmetrical peak of immunoreactivity that was equally reactive in anti-N and anti-C assays; there was no de-DISCUSSION Although several reports describe multiple fragments of iPTH (principally COOH-terminal fragments) in tectable iPTH trailing from this peak (data not shown). FIGURE 3 Gel filtration of 1.8-ml samples of serum from paRechromatography of the pooled components in para-tient I (see Table I Earlier reports from our laboratory (11, 38) and several others (8, 12, 13) have established that there are at least two general types of PTH radioimmunoassays which have different utilities in the diagnosis of parathyroid dysfunction. We found that anti-N assays are most useful in studies of acute secretory dynamics of parathyroid tissue in response to hyper-or hypocalcemic stimuli (41) . As well, this type of assay appears to be better than anti-C assays in the examination of blood samples obtained during catheterization of small veins of the neck and mediastinum for the purpose of localizing hyperfunctioning parathyroid tissue (38, 42) . The results presented in this paper provide an explanation for this observation: we have measured a two-to fourfold greater step-up increase of iPTH in parathyroid or thyroid venous effluents with an anti-N assay than with an anti-C assay because of the lower concentration of iPTH measured with the anti-N assay in peripheral serum. Anti-C assays, on the other hand, have been shown to be superior when applied to the measurement of steady-state levels of iPTH for the Human Parathyroid Hormone 1373 purpose of identifying states of chronic parathyroid hyperfunction (13, 38) . The reasons for this superiority are not known. However, our studies provide a possible explanation: if parathyroid tumors secreted more COOH-terminal PTH fragments, or a higher proportion of these fragments, (or both), than normal tissue, these peptides might be considered "markers" for parathyroid hyperfunction which could be detected better by anti-C assays. Firm evidence confirming the paucity of or total absence ofthese PTH fragments in fractionated sera obtained directly from normal parathyroid glands would be required to support this hypothesis. The existence of biologically active PTH fragments in bovine parathyroid tissue has been recognized for many years (43, 44) . In demonstrating the presence of PTH fragments in extracts of human parathyroid tumors, Silverman and Yalow concluded that these fragments were artifacts originating from degradation of PTH(1-84) during tissue storage or extraction (8) . However, we have recently found that large quantities of biologically inactive, crude COOH-terminal PTH fragments (suitable for producing PTH antisera directed toward the COOH-terminal region of hPTH) can be readily recovered from pooled, frozen human parathyroid tumors (45) , and the results presented in this paper have now shown that COOH-terminal PTH fragments are secreted. One missing piece of information remains before these two observations can be firmly linked: the definitive demonstration that these fragments exist in human parathyroid tissue in vivo. Attention must also be directed toward the physiologic mechanisms for the elaboration of these PTH fragments and the possible roles played by calcium-regulated enzymes ofthe parathyroid gland (46) . Other key questions relate to the control of secretion of these fragments and whether derangements in processes connected with PTH degradation in the parathyroid gland (47) might be a reflection of, or even contribute directly to, the pathogenesis or parathyroid gland dysfunction.
